Personalized Sertraline Dosing in Patients With Depression

UnknownOBSERVATIONAL
Enrollment

148

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

September 30, 2023

Study Completion Date

November 30, 2023

Conditions
Depressive Disorder, Major
Interventions
DRUG

Sertraline

"Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia."

Trial Locations (3)

11000

RECRUITING

Clinical Centre of Serbia, Belgrade

RECRUITING

Institute of Mental Health, Belgrade

NOT_YET_RECRUITING

Military Medical Academy, Belgrade

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Clinical Centre of Serbia

OTHER

collaborator

Institute of Mental Health, Serbia

UNKNOWN

collaborator

Military Medical Academy, Belgrade, Serbia

OTHER

lead

University of Belgrade

OTHER

NCT05210153 - Personalized Sertraline Dosing in Patients With Depression | Biotech Hunter | Biotech Hunter